Rituximab is a modulator of which immune cells?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Prepare for the Dermatology Week 1 Exam with comprehensive study materials. Practice with detailed questions, flashcards, and expert explanations. Boost your knowledge and confidence for the exam!

Multiple Choice

Rituximab is a modulator of which immune cells?

Explanation:
Rituximab directly targets B cells. It binds to CD20, a surface protein present on most mature B cells, and flags these cells for destruction. The main ways this happens are antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, with some ability to induce direct cell death as well. Because CD20 is not on stem cells or plasma cells, rituximab depletes circulating and tissue B cells while sparing others, which reduces antibody production and B-cell–mediated antigen presentation. It does not directly modulate T cells, NK cells, or macrophages, though those cells can participate in clearing the opsonized B cells as part of the process.

Rituximab directly targets B cells. It binds to CD20, a surface protein present on most mature B cells, and flags these cells for destruction. The main ways this happens are antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, with some ability to induce direct cell death as well. Because CD20 is not on stem cells or plasma cells, rituximab depletes circulating and tissue B cells while sparing others, which reduces antibody production and B-cell–mediated antigen presentation. It does not directly modulate T cells, NK cells, or macrophages, though those cells can participate in clearing the opsonized B cells as part of the process.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy